ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Relationship Between Serum HMGB1 and RAGE Levels and Restenosis in Type 2 Diabetes Mellitus Patients Complicated With Lower Extremity Vascular Disease: A Retrospective Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the potential association between the serum concentrations of high mobility group protein B1 (HMGB1) and the receptor for advanced glycation end-products (RAGE) in relation to the occurrence of restenosis following interventional therapy for lower extremity vascular disease in patients diagnosed with type 2 diabetes mellitus (T2DM). Patients and Methods: From March 2023 to January 2024, 96 T2DM patients with lower extremity vascular disease who underwent interventional therapy and 6-month follow-up in our hospital were studied. Patients were divided into in-stent restenosis (ISR) (n=38) and none-in-stent restenosis (NISR) (n=58) groups based on the occurrence of ISR. Pre-surgery demographics and serum levels of HMGB1, RAGE, glycated hemoglobin (HbA1c), and high-sensitivity C-reactive protein (hs-CRP) were analyzed. A Pearson correlation and multivariate Logistic regression were used to identify factors influencing restenosis. A predictive nomogram was built based on the identified factors. The receiver operating characteristic (ROC) curve analysis evaluated the predictive value of serum RAGE and HMGB1 for restenosis post-intervention. Results: The ISR group exhibited statistically significant elevations in HbA1c, hs-CRP, HMGB1, and RAGE levels compared to the NISR group ( Conclusion: Elevated preoperative serum levels of HMGB1 and RAGE in T2DM patients with lower extremity vascular disease are linked to restenosis following interventional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.